Understanding Optogenetic Biomanufacturing: Key Questions for Future Advances

The landscape of biologics manufacturing is evolving as the demand for more sophisticated therapeutics grows. With the emergence of challenging biologics such as multi‑specific antibodies and fusion proteins, conventional bioprocessing methods often fall short. These complex molecules are not only difficult to express at commercially viable yields but also require precise control over production conditions to ensure their quality and efficacy.

Traditional cell line development (CLD) typically relies on static gene expression systems driven by constitutive promoters, generating a continuous production environment. However, this approach can be problematic for next-generation biologics, where there’s a significant trade-off between cell growth and protein production. Emerging methods, particularly those utilizing optogenetics, present promising alternatives by enabling more dynamic control over cellular processes.

1. The Relevance of Optogenetics in Biologic Manufacturing

Optogenetics harnesses light-sensitive proteins to manage specific cellular functions, with a particular focus on regulating gene expression in biomanufacturing. Unlike conventional methods that maintain static expression, optogenetics allows for reversible and tunable control. This flexibility is increasingly vital as biologics become more complex and sensitive, necessitating precise modulation of transcription levels directly, rather than affecting the entire cell through indirect means.

2. Improving Production Efficiency with Light-Based Control

One of the core challenges in biologics manufacturing is the competition between cell growth and protein production. Conventional systems lead to a trade-off where cells that produce high yields often grow slowly, while rapidly dividing cells yield lower protein titers. Optogenetics provides a solution by decoupling these phases. Cells can grow in a non-induced state with minimal strain and then be induced for protein production through light exposure. This process allows for more efficient use of cellular resources, resulting in enhanced productivity and quality.

3. Mechanism and Safety of Light Exposure

Safety is a key consideration in using optogenetics, particularly regarding the effects of light on cells and growth media. Optogenetic systems can be finely controlled using brief, low-intensity light pulses, avoiding continuous high-intensity illumination that could harm cells. Existing research indicates that the wavelengths used in these systems fall within the non-ionizing range and do not negatively impact cellular physiology or DNA integrity, thereby ensuring safe operation during biomanufacturing processes.

4. Lab Operations and Implementation Challenges

Transitioning to optogenetic workflows requires minimal adjustments to existing laboratory setups. Standard equipment suffices, with the primary addition being light devices compatible with bioprocessing instruments. Key adjustments are needed during specific phases, such as pool generation and cloning, where cells must remain uninduced, achieved by working under “safe light” conditions. The operational changes are manageable and generally involve local adaptations to accommodate light exposure.

5. Controlling Multiple Functions within a Single Cell Line

Current optogenetic systems possess the capability to regulate multiple cellular functions using different light wavelengths. For instance, one color can manage protein production while another modulates critical quality-related pathways. This modularity enhances flexibility in biomanufacturing, allowing for more complex and coordinated control as advances in genetic circuit design continue to evolve.

6. Clinical and Commercial Viability of Optogenetically Manufactured Biologics

Progress is already underway in developing optogenetic cell lines for various applications. Regulatory frameworks are being established for assessing emerging biomanufacturing technologies, paving the way for optogenetics to support clinical developments in the near future. If initial results continue to meet expectations, we could see optogenetic processes facilitating clinical filings within two years, followed by broader commercial adoption.

7. Integrating Optogenetics into Existing Facilities

A significant advantage of optogenetic manufacturing is its compatibility with current bioprocessing infrastructures. Existing bioreactors can be retrofitted with optogenetic hardware without the need for major redesigns. For instance, light can be introduced through single-use bags or via illuminated loops in stainless-steel systems, maintaining sterility while enhancing production capabilities.

8. Scaling Up Optogenetic Systems

Scaling optogenetic approaches to larger bioreactors depends on several factors: sensitivity of photoreceptors, longevity of activation in darkness, and the mixing dynamics in the bioreactor. Current optogenetic designs are optimized for low light intensity activation and show promise for scalability, as initial pilot studies have indicated successful results in larger volumes, confirming potential for commercial applications.

9. Adoption by Established Biopharma Players

In the conservative world of biologics manufacturing, the willingness to evaluate new technologies hinges on clear evidence of improved outcomes without introducing additional risks. Significant data demonstrates that optogenetic induction can double titers for standard monoclonal antibodies and more challenging proteins, while also preserving vital quality attributes. As the complexity of therapeutics increases, leading biopharma companies are recognizing the need for advanced manufacturing solutions, making optogenetics a point of interest for strategic evaluation.

10. Future Prospects for Optogenetic Biomanufacturing

Looking ahead, optogenetic control may emerge as a standard methodology for regulating gene expression and cellular functions in biologics manufacturing. This innovative approach promises not only to enhance production efficiency but also to ensure more predictable quality profiles and adaptable facility designs. With continued technological maturation, we anticipate widespread adoption among Contract Development and Manufacturing Organizations (CDMOs), biotechs, and pharmaceutical companies aiming for improved manufacturing control.

Maximilian Hoerner, PhD, currently leads the optogenetics division at Prolific Machines.